Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 2/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.51 |
| ▸ | GABRP | O00591 | 2/20 | 0.49 |
| ▸ | GABRD | O14764 | 2/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.49 |
| ▸ | GABRE | P78334 | 2/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | KAT8 | Q9H7Z6 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072747 | 1.00 | KDM6B (0.51) | KDM6BKDM4CGABRPGABRDGABRA1 | |
| SCHEMBL5002411 | 1.00 | KDM6B (0.51) | KDM6BKDM4CGABRPGABRDGABRA1 | |
| SCHEMBL5002870 | 1.00 | KDM6B (0.51) | KDM6BKDM4CGABRPGABRDGABRA1 | |
| SCHEMBL4998464 | 1.00 | KDM6B (0.51) | KDM6BKDM4CGABRPGABRDGABRA1 | |
| SCHEMBL4005290 | 0.94 | GABRP (0.55) | KDM6BKDM4CGABRPGABRDGABRA1 | |
| SCHEMBL3122447 | 0.88 | KDM4C (0.55) | KDM6BKDM4CGABRPGABRDGABRA1 | |
| SCHEMBL258369 | 0.87 | KDM4C (0.51) | KDM6BKDM4CGABRPGABRDGABRA1 | |
| SCHEMBL9879956 | 0.86 | PTGDR2 (0.45) | KDM6BKDM4CPTGDR2KAT8PPARA | |
| SCHEMBL27449213 | 0.86 | KDM4C (0.56) | KDM6BKDM4CGABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL5739434 | 0.85 | KDM4C (0.50) | KDM6BKDM4CGABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143954-B1 | USE OF NICOTINIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | UNIV KENTUCKY RES FOUND (US) | 2004-08-11 | — | — | EP | claimed |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2004-07-29 | — | — | US | claimed |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2001-10-25 | — | — | US | claimed |
| EP-1143954-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | University of Kentucky Research Foundation (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000032179-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2000-06-08 | — | — | WO | claimed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| US-20240408023-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4171518-B1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | Triastek, Inc. (CN) | 2024-10-17 | — | — | US | disclosed |
| EP-3302442-B1 | DOSAGE FORMS AND USE THEREOF | TRIASTEK INC (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2004-07-29 | — | — | US | disclosed |
| US-6552050-B2 | Adjustment of cellular nicotinamide-adenine dinucleotide | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-04-22 | — | — | US | disclosed |
| US-20020123517-A1 | Reducing cell necrosis or apoptosis by administering a pro-NAD compound such as nicotinic acid or nicotinamide; nicotinamide adenine dinucleotide (NAD); manipulating poly(ADP-ribose) polymerase pathways | JACOBSON ELAINE L (US) | 2002-09-05 | — | — | US | disclosed |
| US-6403619-B1 | TOPICALLY ADMINISTERING PRO-NAD COMPOUND (ESTERS OF NICOTINIC ACID) | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2002-06-11 | — | — | US | disclosed |
| US-6337065-B1 | FOR THERAPY OF DISORDERS SUCH AS SUNBURN AND OTHER SKIN DETERIORATION THAT RESULTS FROM DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2002-01-08 | — | — | US | disclosed |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2001-10-25 | — | — | US | disclosed |
| EP-1143954-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | University of Kentucky Research Foundation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000032179-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | KDM6B 3256/4885KDM4C 3871/4885GABRP 2192/4885 |
| US-20020123517-A1 | Reducing cell necrosis or apoptosis by administering a pro-NAD compound such as nicotinic acid or nicotinamide; nicotinamide adenine dinucleotide (NAD); manipulating poly(ADP-ribose) polymerase pathways | NAMPT, NADK, NAPRT | KDM6B 3227/4885KDM4C 4500/4885GABRP 3389/4885 |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | CYP2D6, CYP3A5, CYP2F1 | KDM6B 3091/4885KDM4C 3560/4885GABRP 1392/4885 |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NQO1, NNT, NAMPT | KDM6B 3566/4885KDM4C 3353/4885GABRP 4421/4885 |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NQO1, NNT, NAMPT | KDM6B 3163/4885KDM4C 3290/4885GABRP 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.